

COVAX

CEPI



unicef



COVAX Allocation Round 12 Vaccine Allocation Decision

IAVG Offline Review – Validated on 22 November 2021

Table of Contents

Background

- ❑ Purpose & Allocation Methodology for Round 12
- ❑ Round 12 Participant Scope
- ❑ Round 12 Supply Scope

Round 12 Proposal

- ❑ Round Outcome - Allocations
- ❑ Descriptive Statistics Summary
- ❑ Overview Graphs
- ❑ Distribution Proposal & Shipment Considerations
- ❑ Conclusions
- ❑ Signatures

IAVG Opinions

- ❑ IAVG Opinions on Current and Future Allocations

Background: Round 12 Supply and Demand

Background

COVAX End-of-Year (EOY) Sprint

COVAX has set two key targets for the next four months

- To ship between 0.8 and 1 billion doses in total by year end
- To ship ~0.9bn doses during Q1 2022

To reach these goals partners across all levels of delivery have been engaged to:

1. Review upcoming deadlines to receive deliveries by EOY and plan for Q1 allocations
2. Share country-level upcoming shipment status and expectations for supply in Q1
3. Work with countries to plan and define Q1 monthly absorption caps by product

Updates to the process

- Donations and APA volumes are being scaled up by donors and manufacturers.
- Visibility of these volumes is extremely short, but volumes are ready for shipment, so all process timelines (allocation, acceptance/refusals, reallocations) have been compressed.
- Following an allocation round, all letters should reach countries within **1 working day**.
- From letter receipt, countries will have no more than **3 working days** to submit a formal acceptance / refusal
- From letter receipt, countries will have no more than **14 working days** to complete preparedness requirements
- To support country preparedness and decision-making, global teams have provided a **“data package”** with information on upcoming shipments and outstanding supply for allocation, as well as a template for collecting information during 1:1 calls with countries

Key November deadlines for countries:

19 Nov: Deadline to refuse / accept any outstanding 2021 allocations

21 Nov: Deadline to submit Q1 monthly absorption caps, by product and additional product preferences through CCP

26 Nov: Deadline to complete preparedness steps to receive outstanding 2021 allocations this year

These deadlines were defined to enable countries to receive outstanding 2021 allocations no later than 31st Dec, accounting for lead times from PO placement to arrival in country

Background

Context for COVAX Allocation Round 12

Context & Purpose

- The first export authorizations have been issued by the Government of India (GoI) for doses from the Serum Institute of India (SII) to the COVAX Facility.
- The JAT, after allocating 25M doses through COVAX Allocation Round 11 (R11), was informed that another 15 million doses of SII-AZ (COVISHIELD™) are available for intended delivery in December 2021.
- As soon as the confirmation of the availability of these additional vaccine from SII was obtained, the JAT allocated these additional quantities following a "non-objection" validation process (also used for R11).
- During the same timeframe, the Facility also received additional information from the countries who could not use their allocation of SII/AZ doses allocated in R11. After receiving a proposal from the COVAX Procurement Coordinator (UNICEF SD), the JAT decided to add these quantities of “refused” doses to the vaccine supply available for Round 12 (R12).
- Furthermore, the Office of the COVAX Facility has informed the JAT that Moderna has agreed to advance the supply available in Q1-2022 for a shipment as early as December 2021. The JAT, therefore, is also allocating around 20M doses of this vaccine.
- In addition, the Facility also received information on countries’ “refusals” of Moderna doses allocated during the Q4-2021. After receiving a proposal from the COVAX Procurement Coordinator, the JAT decided to add these quantities of refused Moderna doses to the vaccine supply available for Round 12 (R12).
- As there has been a rapid increase in vaccine donations and available APA doses in the context of this end of year sprint, the main criteria that has driven the allocation through the algorithm is the remaining absorptive capacity that Participants have signaled to COVAX.

Background

Participant Scope

Participant Scope
COVAX Facility Participants
- There are 89 Advance Market Commitment (AMC) and 73 Self Financing (SFP) participants to the COVAX Facility. - Among the COVAX Facility Participants, there are 65 AMC and 8 SFP participants which are SII-eligible countries, for a total of 73 Participants. Beyond that, the Moderna supply secured by the Facility is available for allocation only to AMC Participants.¹
Round Participant Selection:
- SII and Moderna have an earmarked list of countries to which their products may be commercialized. - Participants eligible to receive an allocation in R12 are those who are under 20% COVAX population coverage through standard allocation rounds only, not including COVAX-facilitated donations. - The following participants were excluded from the list of eligible Pax provided by the manufacturer: - participants marking the vaccine as (highly) undesirable in the COVAX Collaboration Platform (CCP) - participants who have recently communicated to the Facility their intent to refuse the vaccine, marking as voluntary delay - participants who have refused the vaccine in the past round - participants not ready to receive and use the vaccine in Q4 2021, according to the information received from the country itself and from country readiness and country engagement teams.

Participant Summary	
Criteria	Participants (n)
Inclusion	
AMC	89
OP	40
CP	30
Team Europe	3
Total Participants Included	162
Exclusion	
Not in manufacturer(s) earmark (n=66)	- AMC: 0 - SFP: 27 (CP), 37 (OP), 2 (TE)
Voluntary Delay (n=13)	- AMC: 11 - SFP: 1 (CP), 1 (TE)
COVAX coverage greater than 20% not accounting for donations (n=6)	- AMC: 6 - SFP: 0
No additional absorptive capacity for Q4-2021 (n=21)	- AMC: 21 - SFP: 0
Country allocation preference and/or absorptive capacity communication (n=12)	- AMC: 12 - SFP: 0
Refusal of eligible product(s) in recent past (n=6)	- AMC: 6 - SFP: 0
Eligible product(s) (highly) undesirable in CCP (n=8)	- AMC: 7 - SFP: 1 (OP)
Monthly allocation cap lower than eligible product(s) minimum shipment size (n=5)	- AMC: 5 - SFP: 0
COVAX overall coverage higher than R12 achievable equality line (round minimum = 0) (n=4)	- AMC: 4 - SFP: 0
Optional Purchaser-related (n=2)	- AMC: 0 - SFP: 2 (OP)
Total Participants Excluded	143

1. With the exception of 2 AMC Participant, who cannot receive the product as it is manufactured in the United States and cannot be deployed to Participants on the USG sanctions list.

Background

COVAX Allocation Round 12 Supply

Round Supply Considerations	Minimum Shipment Size	
- Allocation Round 12 is an exceptional round relying on supply figures provided to the JAT by the COVAX Procurement Coordinator, UNICEF SD, in conjunction with the Gavi Deals Team <u>with a very short notice</u>. - The supply is as follow: ❑ 19.8 M of SII-AZ vaccine ❑ 23.4 M of Moderna vaccine - The JAT proceeded to allocate these volumes rapidly to allow for the related shipments to take place by the end of this year.	Product Name	Minimum Shipment Size (doses)
	SII-COVISHIELD	18,000
	Moderna	10,080 for total population < 3 million 115,200 for total population > 3 million

Moderna Supply R12		
Initial Supply from Procurement Coordinator		
November 2021	9,582,186 doses	
December 2021	10,417,814 doses	
Total Supply of Moderna Remaining in Q4-2021	20,000,000 doses	
Additional Doses from Confirmed Refusals		
Refused Moderna Doses R7-9	3,400,620 doses	
Total R13 Supply + Refusals for Q4-2021	23,400,620 doses	
Round no.	Participant	Refused Moderna Doses
8,9	Cameroon	3,010,560
8,9	Chad	188,460
8,9	Comoros	120,960
7	Lesotho	80,640
Total		3,400,620

SII/AZ Supply R12	
Initial Supply from Procurement Coordinator	
December 2021	15,000,000 doses
Total Supply of SII/AZ Remaining in Q4-2021	15,000,000 doses
Additional Doses from Confirmed Refusals	
Refused SII/AZ Doses R11	4,864,000 doses
Total R13 Supply + Refusals for Q4-2021	19,864,000 doses
Participant	Refused R11 SII/AZ Doses
Lesotho	219,000
Guinea	333,000
Kyrgyzstan	115,000
Solomon Islands	150,000
Zambia	4,047,000
Total	4,864,000

Background

Humanitarian Buffer

Proposed Allocation to the Humanitarian Buffer	
Product Name	Total Supply (doses)
-	-

Background to Proposed Allocation to the Humanitarian Buffer
• Due to the special circumstances of this Round, the JAT refrained from allocating doses to the Humanitarian Buffer. • Five percent of R12 supply will, however, count towards what is owed to the Humanitarian Buffer across rounds and caught up in upcoming rounds.

R12 Proposal


R12 Allocation Outcome

Participant name	WHO region	COVAX Participation model	SII/AZ Allocation (doses)	Moderna Allocation (doses)	Total R12 Allocation (doses)
Bangladesh	SEAR	AMC92	792,000	7,833,600	8,625,600
Democratic People's Republic of Korea	SEAR	AMC92	4,734,000		4,734,000
Egypt	EMR	AMC92		460,800	460,800
El Salvador	AMR	AMC92		115,200	115,200
Fiji	WPR	AMC92		141,120	141,120
Ghana	AFR	AMC92	1,062,000		1,062,000
Honduras	AMR	AMC92		230,400	230,400
Mauritius	AFR	COMMITTED	90,000		90,000
Morocco	EMR	AMC92		4,608,000	4,608,000
Myanmar	SEAR	AMC92	3,996,000		3,996,000
Namibia	AFR	COMMITTED	450,000		450,000
Nepal	SEAR	AMC92		1,497,600	1,497,600
Nigeria	AFR	AMC92	5,742,000		5,742,000
Pakistan	EMR	AMC92		3,110,400	3,110,400
Somalia	EMR	AMC92	540,000		540,000
Sri Lanka	SEAR	AMC92	2,448,000		2,448,000
Tunisia	EMR	AMC92		921,600	921,600
Ukraine	EUR	AMC92		230,400	230,400
Viet Nam	WPR	AMC92		4,147,200	4,147,200
Grand Total			19,854,000	23,296,320	43,150,320

R12 Allocation Outcome – Descriptive statistics


Total Participants 19	AMC92 participants 89.5%			Committed purchase 10.5%		Population-weighted avg. coverage in round 1.99%		Population-weighted avg. coverage overall 25.39
	Round Coverage				Total Coverage			
Participation Model	Avg. Coverage in Round	Round Median	Round Min	Round Max	Average	Median	Min	Max
AMC92 participants	3.04	2.130286935	0.23	9.18	26.44	27.43523473	12.23	35.52
Committed purchase	6.2	6.201838741	3.55	8.85	26.92	26.92413868	22.79	31.05
OVERALL	3.37	2.56992827	0.23	9.18	26.49	27.43523473	12.23	35.52
Top product percent	Top natural percent	Top historical product percent	Top impartial product percent					
72	50	71.43	83.33					
Total Equity Deviation 0.01	Preference Deviation 0.28			Unique Product Deviation -0.24		Average Unique Products 76		Average Value Of A Course 99.63

Overall Population Coverage after Round 12 – Participants Allocated Doses in Round 12 (n=19)



Note: Participants listed from left to right in increasing order of population, grouped by participation model. COVAX overall population coverage accounts only for doses allocated through COVAX allocations and donations distributed through COVAX.

Overall Population Coverage after Round 12 – All Participants Allocated (n=155)



Note: Participants listed from left to right in increasing order of population, grouped by participation model. COVAX overall population coverage accounts only for doses allocated through COVAX allocations and donations distributed through COVAX.

Distribution Proposal & Shipment Considerations

COVAX Allocation Round 12

Distribution Proposal

- In alignment with the rapid reallocation process due to the EoY sprint, Participants will be notified that they are allotted 14 working days to clear all post-allocation preparedness checks following notification of the Round's outcome.
- Subsequent changes to Participants' total coverage from this Round resulting from the standard reallocation process will be communicated to the Participants upon execution. These modifications will also be visible to the IAVG in the Allocation Portal once completed.

Shipment Considerations

- Should export authorization be obtained, a prioritized shipping order is recommended for distribution of doses allocated in the round. In previous rounds, a decision was taken to inform the sequencing of shipments based on participants' overall achieved coverage from all sources of supply and their epidemiological situation. The JAT will provide this data to the Procurement Coordinator, as has been done in previous rounds.
- The JAT continues to work with the Procurement Agencies to account for the changing context in Facility Participants, particularly relating to absorptive capacity, upcoming shipments of donations, and additional doses coming from cost-sharing deals.
- The Facility recommends that, closer to the date of the planned shipment, the absorption capacity of countries should be reassessed to ensure that all planned quantities can be used by participants before the vaccines' expiry dates.

Conclusion & Signatures

COVAX Allocation Round 12

Conclusion

By 22 November 2021, eleven of the twelve IAVG Members validated this allocation on a non-objection basis, therefore achieving quorum, according to the amounts detailed in **Allocation Round Results** and outlined in the **Round 12 Output** from the WHO Allocation Portal.

The JAT provided further information and details as requested by the IAVG during the 48-hours review window.

Steps

Process Step	Date
The JAT sent R12 indicative allocation proposal to IAVG	19 November 2021
IAVG non-objection validation for R12	22 November 2021
WHO DDG sign-off on R12 allocation decision	22 November 2021
JAT notifies the Office of the COVAX Facility and the Procurement Coordinator	22 November 2021
Country communications dispatched for R12	Beginning on 23 November 2021
IAVG Reports for R12 finalized and published	26 November 2021

Signatures

Signature Assistant Director General, Access to Medicines and Health Products, WHO	Signature Managing Director, Office of the COVAX Facility, Gavi
Obtained via email	Obtained via email
Mariângela SIMÃO	Aurélia NGUYEN
On date: 19 November 2021	On date: 19 November 2021

IAVG Opinion

On the JAT Proposed Allocation

The IAVG considered the JAT's allocation proposal and is of the following opinion:

- The IAVG agreed with the allocation methodology for the COVAX Allocation Round 12, which was:
 - ❑ In the context of the COVAX end-of-year sprint, ensuring that the allocation went to Participants with the capacity to absorb additional doses to be shipped in December 2021, including through increased communication with country-facing staff and the COVAX Country Readiness and Delivery team;
 - ❑ Ensuring that the allocation went to Participants mostly likely to accept the vaccine types allocated. The Participants who either refused the product(s) in the last few months, or who marked the product(s) as 'undesirable'/'highly undesirable' in the COVAX Collaboration Platform (CCP) were marked as ineligible for this allocation.
- The IAVG raised the following points:
 - ❑ The IAVG was supportive of this Round's contribution to overall coverage in Participants who had to date achieved a relatively lower population coverage through COVAX-secured doses, including to some Participants with relatively less reported data on the burden of COVID-19 in country and who may be at risk and requiring additional attention.
- The IAVG underlines the following concerns :
 - ❑ The IAVG continues to be concerned of the effects that manufacturer-specific earmarking may have on equity in COVAX-secured coverage across all the Facility Participants;
 - ❑ The IAVG raised concerns about the extremely short notice provided to Facility Participants to update their allocation preferences in terms of vaccine types and monthly maximum allocation capacities for the end-of-year sprint;
 - ❑ The IAVG requested more information on the shelf-life of allocated vaccine to ensure that Participants receiving these doses during this last month of 2021 will have sufficient time to administer them.